Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
In the trading session that priced this news, ABOS gained 4.89%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming conferences:
- The Alzheimer’s Association International Conference (AAIC), in San Diego and virtually, from Sunday, July 31, to Thursday, August 4, 2022
- Acumen scientists will present a poster, “Preparation and qualification of soluble amyloid beta oligomers for use in bioanalytic assays supporting Alzheimer’s disease therapeutics,” (P4-178) on August 3
- The BTIG Biotech Conference, in New York and virtually, on Monday, August 8, 2022 at 2:00 pm ET
- Dr. Eric Siemers, Chief Medical Officer, will be participating in an AD panel: “The Next Generation of Anti-Amyloid and Anti-Tau Targeting Therapeutics for Alzheimer's Disease”
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, headquartered in Charlottesville, Va. with clinical operations based in Carmel, Ind., is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on toxic soluble AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.
Contacts:
Media:
AcumenPR@westwicke.com
Investors:
investors@acumenpharm.com
